Marshall Wace North America’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Marshall Wace North America’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$55.4M	Buy	505,691 +487,118	+2,623%	+$50.6M	0.24%	88
2021 Q2	$1.74M	Sell	18,573 -211,437	-92%	-$19.5M	0.01%	846
2021 Q1	$21.2M	Sell	230,010 -447,005	-66%	-$37.7M	0.09%	248
2020 Q4	$49.5M	Buy	677,015 +25,709	+4%	+$1.91M	0.22%	118
2020 Q3	$50.6M	Sell	651,306 -465,441	-42%	-$32M	0.32%	73
2020 Q2	$62.1M	Buy	1,116,747 +230,653	+26%	+$9.87M	0.41%	58
2020 Q1	$26.2M	Buy	886,094 +593,869	+203%	+$20.1M	0.2%	136
2019 Q4	$10.6M	Buy	292,225 +34,526	+13%	+$1.06M	0.05%	277
2019 Q3	$7.02M	Buy	257,699 +87,277	+51%	+$2.26M	0.04%	303
2019 Q2	$4.1M	Sell	170,422 -147,432	-46%	-$3.74M	0.03%	405
2019 Q1	$8.4M	Buy	317,854 +202,785	+176%	+$4.81M	0.06%	231
2018 Q4	$2.25M	Buy	+115,069	New	+$2.26M	0.02%	406
2018 Q2	–	Sell	-189,843	Closed	-$2.7M	–	1885
2018 Q1	$2.7M	Sell	189,843 -940,011	-83%	-$13.9M	0.01%	731
2017 Q4	$16.5M	Buy	+1,129,854	New	+$15.9M	0.09%	263

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Marshall Wace North America's HZNP Position: Q3 2021 in Review

Marshall Wace North America increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 2,623% in Q3 2021, buying an estimated $50.6M and bringing the position to 505,691 shares worth $55.4M. The position accounts for 0.24% of the portfolio, ranked #88.

Marshall Wace North America first reported a position in HZNP in Q4 2017 and has held it in 14 quarters since. The position peaked at $62.1M in Q2 2020. 572 funds tracked by Wall St. Rank hold HZNP as of Q3 2021.

Marshall Wace North America held 505,691 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $55.4M as of Q3 2021.
Marshall Wace North America bought 487,118 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2021, an estimated $50.6M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.24% of Marshall Wace North America's portfolio in Q3 2021, its #88 holding.
Marshall Wace North America first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and has held it in 14 quarters since.
Marshall Wace North America's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $62.1M in Q2 2020.
572 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.